Tarsus Pharmaceuticals Inc (TARS)
38.57
+0.58
(+1.53%)
USD |
NASDAQ |
May 15, 16:00
38.57
0.00 (0.00%)
After-Hours: 16:11
Tarsus Pharmaceuticals Profit Margin (Quarterly): -129.4% for March 31, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -129.4% |
| December 31, 2023 | -320.4% |
| September 30, 2023 | -2.09K% |
| June 30, 2023 | |
| March 31, 2023 | -936.8% |
| December 31, 2022 | -136.0% |
| September 30, 2022 |
| Date | Value |
|---|---|
| June 30, 2022 | -37.59% |
| March 31, 2022 | -3.75K% |
| December 31, 2021 | -4.39K% |
| September 30, 2021 | -1.27K% |
| June 30, 2021 | 28.82% |
| March 31, 2021 | 31.04% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-4.39K%
Minimum
Dec 2021
31.04%
Maximum
Mar 2021
-1.18K%
Average
-320.4%
Median
Dec 2023
Profit Margin (Quarterly) Benchmarks
| Pacira BioSciences Inc | 5.37% |
| Unicycive Therapeutics Inc | -- |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | -19.35K% |
| IGC Pharma Inc | -2.74K% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -73.59% |
| Return on Assets | -57.75% |
| Return on Invested Capital | -64.69% |
| Gross Profit Margin (Quarterly) | 94.01% |
| Operating Margin (Quarterly) | -136.5% |
| Return on Net Operating Assets | -599.6% |